ROIV logo

ROIVANT SCIENCES LTD

ROIVNASDAQ
🏆 #437 by market capEarnings Nov 9US Equity
$37.10▲ $0.53 (+1.44%)
Market closed · at close
🔔
Track ROIV
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 1.4%
7d▼ 0.9%
14d▲ 8.9%
30d▲ 1.6%
ytd▲ 71.0%
1y▲ 97.7%
🏦Market Cap
$26.79B
Mid Cap
📈Revenue Growth (YoY)
-67.6%
Declining
📊Gross Margin
81.2%
High
💵FCF Margin
—
⚖️P/S Ratio
3504.2x
Expensive
Otter Score
52
Fair

Trading Snapshot

Day Range
$36.17 – $37.13
52-Week Range
$18.27 – $42.50
Volume (shares)
301,989
Avg Volume (shares)
—
Shares Outstanding
722.3M
Next Earnings
2026-11-09

Fundamentals Snapshot

Annual Revenue
—
Last Q Revenue
—
P/E Ratio
—
P/S Ratio
3504.2x
EPS (TTM)
$-0.39
Dividend Yield
—
Dilution (1yr)
+3.4%
ROIV logo

ROIVANT SCIENCES LTD

ROIV
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$8M▼ −71.6% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
84.4%▼ −12.8% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$1.3B▲ +15.4% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$759M▼ −10.1% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
720.8M▲ +3.4% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$1.1B▼ −$130M YoY
StockOtter · stockotter.space

About ROIVANT SCIENCES LTD

Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company dedicated to discovering and advancing innovative therapeutic drugs. The firm's development pipeline targets a broad spectrum of diseases, including various forms of solid tumors and oncologic malignancies, hematological disorders like sickle cell disease and warm autoimmune hemolytic anemia, as well as rare conditions such as hypophosphatasia. Additionally, Roivant is developing treatments for immunological and dermatological ailments, including psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, thyroid eye diseases, and sarcoidosis, alongside tackling infections like staph aureus bacteremia. Founded in 2014, its operations are based in London, United Kingdom.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
52/100

Analyst Ratings

ⓘ
Consensus
Buy
20 analysts
Strong Buy9
Buy9
Hold2
Sell0
Strong Sell0
Ratings as of Oct 2026

Latest News & Updates

News unavailable.